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 IRF8 is associated with a GCB-type of DLBCL and 
exceptionally involved in a translocation t(14;16) 
(q32.33;q24.1) 
 Marianne  Tinguely ,  Svenja  Thies ,  Simona  Frigerio ,  Tanja  Reineke , 
 Dimitri  Korol , Dieter R.  Zimmermann 
 10.3109/10428194.2013.793324 
 Abstract 
 Chromosomal translocations involving the immunoglobulin loci repre-
sent frequent oncogenic events in B-cell lymphoma development. 
Although IRF8 (ICSBP-1) protein expression has been demonstrated 
in germinal centre B-cells and related lymphomas in a single report, 
the  IRF8 gene was not described as an IGH translocation partner. 
      In a discovery driven approach we searched for new translocation 
partners of the IGH in DLBCL by long distance inverse (LDI) PCR 
and Sanger sequencing. A t(14;16)(q32.33;q24.1)  IGH/IRF8 was 
detected in a CD5+ de novo DLBCL, confi rmed by translocation 
specifi c PCR and FISH analysis. No further IRF8 aberration could be 
identifi ed neither by LDI-PCR in additional fi ve CD5+ DLBCL nor by 
FISH on 78 FFPE biopsies. Subsequent screening for IRF8 by 
immunohistochemistry revealed IRF8 expression in 18/78 (23%) 
correlating with a GCB type of DLBCL. This hitherto unknown 
translocation t(14;16)(q32.33;q24.1) is alike to represent the initiator 
of a multistep lymphomagenesis in a CD5+ de novo DLBCL. 
 Key words translocation, IRF8, ICSBP-1, DLBCL, 
CD5 de novo DLBCL, long distance inverse PCR 
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ABSTRACT 
Chromosomal translocations involving the immunoglobulin loci represent 
frequent oncogenic events in B-cell lymphoma development. Although IRF8 
(ICSBP-1) protein expression has been demonstrated in germinal centre B-cells 
and related lymphomas in a single report, the IRF8 gene was not described as 
an IGH translocation partner. 
In a discovery driven approach we searched for new translocation 
partners of the IGH in DLBCL by long distance inverse (LDI) PCR and Sanger 
sequencing. A t(14;16)(q32.33;q24.1) IGH/IRF8 was detected in a CD5+ de 
novo DLBCL, confirmed by translocation specific PCR and FISH analysis. No 
further IRF8 aberration could be identified neither by LDI-PCR in additional five 
CD5+ DLBCL nor by FISH on 78 FFPE biopsies. Subsequent screening for 
IRF8 by immunohistochemistry revealed IRF8 expression in 18/78 (23%) 
correlating with a GCB type of DLBCL. This hitherto unknown translocation 
t(14;16)(q32.33;q24.1) is alike to represent the initiator of a multistep 
lymphomagenesis in a CD5+ de novo DLBCL. 
 
Key words translocation, IRF8, ICSBP-1, DLBCL, CD5 de novo DLBCL, long 
distance inverse PCR 
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0BIntroduction 
Chromosomal translocations involving the immunoglobulin loci represent 
frequent oncogenic events in B-cell lymphoma development. They are generally 
initiated by accidental double strand breaks of oncogenes and by regular double 
strand cleavage occurring in conjunction with the physiological V(D)J 
rearrangement or class switch recombination processes during B-cell 
maturation. The translocation is finally the result of an erroneous double strand 
repair linking the wrong ends of the disrupted DNAs. Consequently, the 
incoming partner gene comes under the control of the IGH locus and is thereby 
de-regulated P1,2P. As described above, IGH gens undergo molecular 
rearrangements in an orchestrated way dependent on their maturation state. 
Therefore, the knowledge of the alignment of functional rearrangements of the 
IGH allows to draw conclusions at which maturation step a malignant 
transformation occured P1,3P. LDI-PCR is a three step method, which allows the 
rapid amplification of un-characterized DNA sequences (such as unknown 
translocation partners) neighbouring a known genomic region (such as IGH). 
The PCR template is a self-ligated circularized DNA, reason for, the primer set 
of the known nucleotide sequence is in opposite orientation. Together with a 
thermostable DNA polymerase, this method was initially used for rapid cloning 
of the IGH joining region P4P. 
Hence, the aim of our study was to find new translocations involved in 
the pathogenesis of DLBCL. For this purpose, we established an LDI-PCR 
approach for an initial screening for novel IGH-translocation partners in fresh 
frozen tissues, and we extended the study on one particular candidate gene by 
analysing a larger cohort of lymphomas in a tissue micro array (TMA) setting 
employing immunohistochemistry and interphase FISH techniques. 
1BMaterials and Methods 
7BPatients and Specimen Selection 
All histological diagnosis were initially reviewed on whole sections 
according to the current WHO classification and further sub-classified according 
to the Hans’ classifier into GCB and non-GCB type P5,6P. The investigation of the 
target gene by LDI-PCR was carried out on fresh frozen biopsies of a total of six 
patients with a CD5+ DLBCL, four of them with a CD5+ de novo DLBCL 
(including the index patient) and one each with Richter transformation and 
transformed lymphoplasmocytic lymphoma/M. Waldenström. Additionally, 
formalin fixed, paraffin embedded biopsies of 78 patients diagnosed for DLBCL 
between 1990 and 1999 were investigated on a TMA. The index patient was a 
female of 73 years of age, who died 24 days after diagnosis of lymphoma. 
This study was done in accordance with Swiss laws and approved by the 
official authorities of the ethical committee of the Canton Zurich (StV26-2006). 
2BLDI-PCR 
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DNA was isolated from snap-frozen tumour specimens using standard 
protocols P7P. In a first step 500-800 ng of high quality DNA was digested with the 
restriction enzymes BgIII, HindIII, XbaI or SphI, each cleaving near the joining or 
switch region of the IGH gene, respectively (Fig1). The digested DNA was 
purified by QiAquick gel extraction kit (Qiagen) followed by a ligation step. In a 
total reaction volume of 50 μl, 5.0 μl QiAquick eluate of the restriction digest was 
added to 5.0 μl X ligase buffer (Roche, Switzerland) and 2U high concentration 
ligase (0.2 μl), and ligated at 16°C over night. Long range PCR was carried out 
using 0.2 μM primer concentration with cycling conditions as published 
previously P7P. For long distance inverse PCR inversely oriented primer pairs 
located in the vicinity of Eμ-enhancer or the switchμ region were employed. 
PCR products were subjected to electrophoresis on 0.5% agarose gels, bands 
were excised, purified with QiAquick gel extraction kit and directly sequenced. 
The sequence was compared to the Genbank and IMGT/Quest databases using 
BLASTN. The new translocation was verified by translocation specific PCR on 
different starting materials including snap frozen and paraffin embedded tissue 
of the index patient IgVH mutation analysis was carried out as published P8P. In 
addition to framework FR3 and FR2a primers combined with a consensus JH 
primer, family specific primers for VH4L and the above consensus primer were 
applied for the determination of the mutational status. For primers see (Table1). 
3BFISH 
The FISH probe for IRF8 was biotin-labeled by nick translation. Detection 
was done with tetramethylrhodamine-5-(and-6)-isothiocyanate (5(6)-TRITC) 
conjugated avidin and included an amplification step with biotinyliated goat anti-
avidin (BioGAA)P9P. The corresponding BAC clone had been verified beforehand 
by PCR with primers specific for IRF8 and by direct sequencing of a 300 bp long 
PCR fragment. Customized FITC labelled IGH probes (Chrombios, Raubling, 
Germany) were admixed to the IRF8 probe. In addition, commercially available 
break-apart LSI probes for IGH, BCL-2, BCL-6, MYC and a fusion probe for 
IGH/CCND1 (Abbott molecular) were applied according to the manufacturer’s 
instruction. For primers and BAC clones see (Table 1). 
8BImmunohistochemistry 
Immunohistochmistry for lymphoma classification was performed as 
published recently P10P. A rabbit polyclonal antibody (H-70; Santa Cruz 
Biotechnology) raised against a recombinant C-terminal fragment of the ICSBP-
1 protein (amino acids 357-426) was used. All techniques were carried out on 
an automated Ventana instrument using a diaminobenzidine immunoperoxidase 
detection kit (Roche’s Ventana Medical Systems, Basel, Switzerland). Double 
staining for DAB was carried out with an Ultra View Universal AP Red Detection 
Kit (Roche’s Ventana Medical Systems, Basel, Switzerland). The staining 
pattern in reactive tonsils served as reference for the antibody quality (Fig2). 
An immunoreactivity score according to Bittinger and Brochhausen was 
calculated by multiplying the staining intensity (IS: 0-3) with the percentage of 
positive cells (PP: 0-100%) P11P. Score 1 (score 1 or <30% IS 1-2) and score 2 
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(score 1-2 or <30% IS 2) were regarded as negative, whereas score 3 (score 2 
or <30% IS 3) and score 4 (score 3 or > 50%) were regarded as positive 
staining. 
9BStatistics 
Correlation between IRF8, GCB and non-GCB type of DLBCL were 
carried out using a two-sided Fisher’s exact test. P-values <0.05 were 
considered significant. Overall survival analysis was estimated with the Kaplan-
Meier method. OS was determined from the date of histological lymphoma 
diagnosis to the date of disease related death of any cause or last follow-up. 
Statistical analysis was performed using the software package SPSS® (Version 
12.0.1 for Windows®, ©SPSS Inc., Chicago, USA). 
4BResults 
In a de novo CD5+ DLBCL a translocation joining the JH2 region of the 
IGH gene on chromosome 14q32.33 with a sequence localised about 500 bp 
upstream of the IRF8 gene on chromosome 16q24.1 was identified by LDI-PCR 
and sequencing. The breakpoint was subsequently verified by standard PCR of 
DNA-extracts of fresh frozen as well as of paraffin embedded tissues from the 
index patient (Fig1). Interphase FISH analysis showed a split signal of one 
allele of the IGH gene with an IGH break-apart probe and a fusion of the IGH- 
and IRF8-signal with the double colour single fusion approach in the same 
lymphoma (Fig2E-F). Moreover, we detected somatic hyper-mutations in the 
variable region of the second IGH allele, characteristic of a germinal centre (GC) 
reaction. No indications for the presence of breaks involving the CCND1, BCL-2, 
BCL-6 or MYC gene could be found neither by LDI PCR nor by conventional 
interphase FISH. Immunohistochemistry revealed a strong IRF8 protein 
expression (score 4) in the CD20 positive tumour cells (Fig3C). 
In the tissue microarray study, 18/78 (23%) DLBCL showed evidence for 
an overexpression of IRF8 (immunohistochemical staining score 3 and 4) 
(Fig2), significantly associating with a GCB-phenotype (CD10+/Bcl-6+/IRF4-) 
(p=0.012), but inversely correlating with an IRF4 expression (p=0.001). Among 
the 78 patients represented on the TMA, there was one with a CD5+ positive, 
non-GCB type DLBCL showing a faint staining (score 2) for IRF8 which was 
regarded as negative. Survival data of 32 out of 78 patients were available, but 
no correlation of IRF8 expression with overall survival could be found (p=0.385). 
No further t(14q32.33;16q24.1) translocation could be identified by LDI-PCR in 
the remaining five frozen tissues of CD5+ DLBCL nor in the 78 formalin-fixed 
DLBCL biopsies analysed by FISH on the TMA. 
5BDiscussion 
We describe a hitherto unknown translocation t(14q32.33;16q24.1) 
joining the IGH and the IRF8 loci in a de novo CD5+ DLBCL. As shown by 
sequence analysis of the LDI-PCR product, and underscored by the IGH FISH 
analysis, the translocation occurred on one allele most likely during the VDJ 
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rearrangement process in the bone marrow. Apparently, the RAG1/RAG2 
recombination enzyme complex cleaved the JH region of the IGH gene 
regularly. In contrast, the breakpoint immediately upstream of the IRF8 may 
have been caused accidentally without participation of the RAG-enzymes as no 
cryptic recombination signal sequence (RSS) could be identified in its vicinity. 
Somatic hyper-mutations in the variable region of the second normally 
rearranged IGH allele, which is characteristic of a germinal centre (GC) reaction, 
indicates further progression of B-cell maturation. Additionally, the variable 
expression of IRF4/MUM1 in some, but not all of the lymphoma cells suggests a 
transit through the germinal centre (GC) after having acquired the somatic 
mutations. 
The translocation partner gene encodes interferon (IFN) consensus 
sequence binding protein-1 (ICSBP-1) also designated as IFN regulatory factor-
8 (IRF8). This protein belongs to the family of IRF transcription factors. IRF8 
regulates multiple stages of immune response, particularly through macrophage 
function P12,13P. Furthermore, the related IRF transcription factors IRF4/MUM1 and 
IRF8 seem to be required for the immunoglobulin light chain, but not the heavy 
chain gene rearrangement in mice P14P. Since the IRF8 can act as a transcriptional 
repressor as well as an activator, its ultimate function is defined by the 
interacting partner proteins (reviewed in P14,15P). 
Here, we confirm the result of a recent study, showing IRF8 expression 
associated with a GC phenotype P16P. The fact, that we were not able to associate 
IRF8 expression with survival, in spite of its association with a GCB-type of 
DLBCL, might be explained with the very heterogeneous treatment modalities 
used during recruitment time and/or in the classifier applied. IRF8 expression in 
nearly one fourth of DLBCL (18/78, 23%) speaks in favour of a hazardous 
association with the index CD5+ DLBCL, but not for a general pattern in primary 
or secondary CD5+ DLBCL. Accordingly to these observations, although easily 
applicable, IRF8 appears not bear prognostic potential in DLBCL. 
However, by demonstrating a specific IRF8/IGH translocation, we 
provide strong evidence that a deregulated expression of IRF8 participates in 
the oncogenic process. In the lymphoma cells of our index patient, we 
hypothesize that IRF8 had come under the control of the IGH enhancers similar 
to other genes erroneously linked to the IGH-locus. Despite the over-expression 
of IRF8 observed in about one fourth of DLBCLs, mechanisms different than a 
gene activation via the t(14q32.33;16q24.1) translocation may be responsible. 
One could hypothesize that the recently described IRF8 mutations described in 
a few DLBCLs (in 4 out of 73 (5.47%) primary DLBCL and in one cell line) may 
be linked to an altered expression in at least some of the cases in our patients' 
collective17. Yet, in our index lymphoma we did not identify any mutation in the 
coding sequences of the IRF8 gene. Moreover, in contrast to newly described 
translocations activating IRF4 in GC derived lymphomas in children and young 
adults, IRF8 seems to be a rare IGH-translocation partner in adults 18. 
Anticipating a potential heterogeneity among the breakpoint localizations near 
the IRF8 gene in different DLBCL patients, we opted for a single fusion FISH 
approach for the screening for similar t(14;16) translocations in the TMA, while 
accepting a slight reduction in sensitivity in comparison to a break apart assay. 
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Translocations with IGH involvement are generally frequent in B-cell 
lymphomas, mostly representing aberrant bystanders of physiological 
rearrangement processes, such as V(D)J recombination or switch recombination 
(CSR) (reviewed in P2,19 P). However, most of these translocations are alone 
insufficient to drive lymphomagenesis. Additional mutations are usually required 
for full transformation to malignant disease P2,19 P. We therefore propose a 
multistep model for the lymphomagenesis in our index patient: The 
t(14q32.33;16;24.1) translocation represents presumably the initial transforming 
event early in the B-cell ontogeny. It affected only one allele without interfering 
with further B-cell maturation. The other IGH allele rearranged normally. 
Additional transforming events apparently occurred later after antigen contact 
and GC reaction. Probably only then, the proliferation of the mature 
translocation carrying B-cells was finally unleashed for the ultimate progression 
to the diffuse large B-cell lymphoma (Fig4). 
Taken together, we demonstrate that the combined application of LDI-
PCR and interphase FISH represent useful screening tools for the detection of 
new translocations as well as determination of their incidence in DLBCL on a 
large patient cohort. However, although IRF8 is widely expressed in DLBCL the 
mechanism by which it is overexpressed needs still to be elucidated. 
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Figure legends 
Fig 1 
Summary of the translocation t(14;16)(q32.33;q24.1) related findings: 
“Chromosomes” Chromosomal map illustrating the involved genes and the 
FISH probes next to the idiograms “Restrictions/Primers” indicates the 
restriction sites and primer locations used for the LDI-PCR screening, depicted 
above the relevant portions of the IGH gene. “Genes/Fusions” IGH/IRF8 
fusion as determined by LDI-PCR and sequencing analysis. The breakpoint on 
the IGH locus occurs in the joining region near the 5’ end of the JH2 element, 
providing evidence that the translocation occurred during the VDJ 
rearrangement early during the B-cell maturation. On chromosome 16q24.1 the 
breakpoint is located about 500 bp upstream of transcription initiation site of the 
IRF8 gene, a transcription factor of the interferon (IFN) regulatory factor (IRF) 
family. Arrows under the gene names indicate the orientation of the coding 
strand. 
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Fig 2 
Immunohistolological and in situ hybridisation analyses. A: Germinal centre-
focused nuclear staining for IRF8 in a reactive tonsil. B: Corresponding control 
staining omitting secondary antibodies. C and D: Representative examples of 
IRF8 immunstainings in different DLBCL tissue cores of a TMA demonstrating 
presence or absence of IRF8 expression, respectively. E-G: Interphase FISH 
with gene probes specific for IGH (FITC labelled; green) and IRF8 (TRITC 
labelled; red). Cells of the CD5+DLBCL of the index patient showing yellow 
fusion signals, indicative of a t(14;16)(q32.33;q24.1) translocation that joins the 
IGH and IRF8 loci (E, F). The corresponding FISH staining of a translocation-
negative DLBCL displays split signals (G). 
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Fig 3 
Index patient with DLBCL A: Giemsa stain showing an aggressive lymphoma 
consisting of cohesive sheets of blasts with many mitotic figures. B: Membrane 
positivity for CD5. C: double stain for membranous CD20 (red) and nuclear IRF8 
(brown) D: Interphase FISH with IGH break-apart probe showing one normal 
allele (green-red fusion = yellow dot) and two split signals (green and red), 
indicating a break in the IGH locus. 
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Fig 4 
Hypothetical sequence of the multistep transformational process in the index 
patient. The translocation represents the primary hit in an immature B-cell in the 
bone marrow followed by an unknown secondary event after germinal centre 
reaction in the mature B-cell. 
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Table Legend 
Table 1 
Primers for PCR and probes for interphase Fluorescence in Situ Hybridization 
(FISH) 
LDI-PCR:    IGH Region primers
Designation Sequence 
Low7836JH6 
Low8577Em: 
Up8716BglII: 
Up9391HindIII: 
Up9879Xba: 
Switch mu upper 
Switch mu lower 
5' 
TAGCAGAAAACAAAGGCCCTAG
AGT 3' 5' 
CAGACACATATCACTCATGGGT
GTT 3' 5' 
GAAGCTGGAAGCAGATGATGA
ATTA 3' 5' 
PCR:    Translocation-specific primers
Designation Sequence 
Chr 16 
JH2 
5’ 
AGCCGCTCCTGGGT
GG 3’ 5’
PCR:    IGH-specific primers 
Designation Sequence 
FR3 
FR2a 
JH 
VH4L 
5’ ACACGGC(C/T)GT(G/A)TATTACTGT 3’ 
5’ 
TGG(A/G)TCCG(A/C)CAG(C/G)C(C/T)(C/T)C(A/C/G/T)G
G 3’ 
5' ACCTGAGGAGACGGTGACC 3' 
FISH assay: BAC clones 
Gene Clone name 
IRF8/ICSBP1 
IGH (by Chrombios) 
RP11-542M13 
RP11
-
249
M16 
RP11
PCR: BAC clone-specific primers
Designation Sequence 
RP11-542M13 IRF8E8up 
RP11-542M13 IRF8E8low 
5’ 
CTGCTGCTGCGGG
AGT 3’ 5’
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